Caziant — Class III drug recall D-1436-2012
Terminated recall by Watson Laboratories Inc, reported 2012-08-08, distributed nationwide. Impurities/Degradation Products: High Out-of-specification results were obtained for both known and unknown im
| Recall number | D-1436-2012 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Watson Laboratories Inc, Corona, CA, United States |
| Recall initiated | 2012-06-05 |
| Classified | 2012-08-01 |
| Reported by FDA | 2012-08-08 |
| Terminated | 2013-03-18 |
| Distributed | Nationwide (US) |
| Quantity | 18,938 cartons |
| Reason classes | specification failure |
| NDC | 52544-0959-28, 52544-0959-31 |
| Lot numbers | 11/12, 412572A, 412572B |
Product
Caziant (desogestrel and ethinyl estradiol) Tablets, USP, (Triphasic Regimen), 0.1 mg/0.025 mg, 0.125 mg/0.025 mg, 0.15 mg/0.025 mg, 28-count tablets per dispenser (NDC 52544-959-28), packaged in 3-count Tablet Dispensers per carton (NDC 52544-959-31), Rx only Manufactured by: Watson Laboratories, Inc., Corona, CA 92880; Distributed by: Watson Pharma, Inc., Corona, CA 92880.
Reason for recall
Impurities/Degradation Products: High Out-of-specification results were obtained for both known and unknown impurities.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1436-2012. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.